Samsung Biologics (207940.KS) unveiled process innovations that shorten biopharmaceutical development timelines by about 27% and double cell culture productivity at a global bioindustry conference.
The company said on the 28th that it took part in BioProcess International (BPI) 2026, held in Boston from the 22nd to the 25th local time, where it presented its manufacturing process innovation strategy and technological capabilities.
BPI is an event where companies share the latest technologies across biopharmaceutical development, production and analysis, and discuss cooperation among global firms. This year's edition drew about 250 companies and more than 3,000 bio industry professionals from around the world.
Samsung Biologics, which has attended BPI for nine consecutive years since 2018, again set up its own booth to promote its ability to support the full biopharmaceutical cycle, from contract research (CRO) to contract development (CDO) and contract manufacturing (CMO). It highlighted Samsung Organoid, its differentiated CDO services and its multi-modality production capabilities.
The company also disclosed technical results that shortened development timelines and improved production efficiency. Lee Tae-hee, head of the antibody and cell purification process development team and a senior vice president at Samsung Biologics, gave a presentation titled "From Complexity to Confidence." Lee described a case in which molecule-specific process design, based on integrated chemistry, manufacturing and controls (CMC), cut development time to 9.5 months from 13 months, a reduction of about 27%, while maintaining high quality.
In the poster sessions, the company showcased advances in cell line development and culture processes. Kim Young-hee, head of the cell line development group, introduced a cell line development platform optimized for complex molecules and presented a strategy for managing drug quality and efficacy simultaneously from the earliest stages of development. Lee So-jung, head of the cell culture process development group, disclosed results achieved with S-Tensify, the company's proprietary culture process intensification platform, which raised cell culture density and doubled titer, a measure of output, from previous levels.
Samsung Biologics also participated in an international conference on cell and gene therapies held alongside BPI, where it presented quality analysis technology for gene therapies. Garcia Abigail, head of the AAV technology group, presented a full capsid analysis strategy for assessing the proportion of adeno-associated virus (AAV) particles that properly contain the therapeutic gene. The approach offers quality assessment criteria aimed at improving the efficacy and safety of gene therapies.
"Through this year's BPI, we showcased our ability to support the entire biopharmaceutical cycle from CRO to CDO and CMO, along with our differentiated technology," said James Choi, executive vice president for sales support at Samsung Biologics. "We will continue to strengthen our position in the global bio market based on advanced technology and services."
